The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Loko, Marc Arthur ^a   Salmon, Dominique ^b,c   Carrieri, Patrizia ^d,e,f   Winnock, Maria ^a   Mora, Marion ^d   Merchadou, Laurence ^a   Gillet, Stéphanie ^a   Pambrun, Elodie ^a   Delaune, Jean ^a   Valantin, Marc Antoine ^a,g   Poizot Martin, Isabelle ^d,h   Neau, Didier ⁱ   Bonnard, Philippe ^j   Rosenthal, Eric ^k   Barange, Karl ^l   Morlat, Philippe ^a,m   Lacombe, Karine ⁿ   Gervais, Anne ^o   Rouges, François ^p   See, Alain B ^q   Lascoux Combe, Caroline ^r   Vittecoq, Daniel ^s   Goujard, Cécile ^t   Duvivier, Claudine ^c,u   Spire, Bruno ^d,e,f   Izopet, Jacques ^l   Sogni, Philippe ^b,c   Serfaty, Lawrence ⁿ   Benhamou, Yves ^g   Bani Sadr, Firouzé ^b,j   Dabis, François ^a   more..

^a INSERM   (France)

^b AP HP ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d AIX MARSEILLE UNIV   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h HÔPITAL SAINTE MARGUERITE   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j HÔPITAL TENON   (France)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^l CHU PURPAN   (France)

^m HÔPITAL SAINT ANDRÉ   (France)

ⁿ HÔPITAL SAINT ANTOINE   (France)

^o BICHAT HOSPITAL   (France)

^p AVICENNE HOSPITAL   (France)

^q hopital Joseph Ducuing   (France)

^r SAINT LOUIS HOSPITAL   (France)

^s HÔPITAL PAUL BROUSSE   (France)

^t BICÊTRE HOSPITAL   (France)

^u HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BEHAVIOR; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ENDOSCOPY; ETHNIC GROUP; FEMALE; FOLLOW UP; FRENCH LANGUAGE; GENOTYPE; HEALTH STATUS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFORMATION PROCESSING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; MORTALITY; ORGANIZATION; PATIENT MONITORING; QUESTIONNAIRE; SEX; SOCIOECONOMICS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; BLOOD; DISEASE COURSE; FRANCE; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; LIVER TUMOR; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; PATIENT COMPLIANCE; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARCINOMA, HEPATOCELLULAR; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; FRANCE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 77958028550     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-303     Document Type: Article

References (36)

1. Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, et al. Prévalence des coinfections par les virus des hépatites B et C dans la population VIH+, France, juin 2004. Bull Epidemiol Hebd 2005, 23:109-12. [French].
2. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004, 38:128-33. 10.1086/380130, 14679458.
3. Martinez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin-Herrera L, Perez-Guzman E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003, 36:491-8. 10.1086/367643, 12567308.
4. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003, 52:1035-40. 10.1136/gut.52.7.1035, 1773713, 12801963.
5. Carlos Martin J, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004, 5:125-31. 10.1310/YFV8-FE5K-5LN9-DQ4C, 15248136.
6. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-5. 10.1016/S0140-6736(00)03232-3, 11117912.
7. Haydon GH, Flegg PJ, Blair CS, Brettle RP, Burns SM, Hayes PC. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 1998, 10:485-9. 10.1097/00042737-199806000-00009, 9855064.
8. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 2009, 10:282-9. 10.1111/j.1468-1293.2008.00686.x, 19226410.
9. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study. J Hepatol 2009, 50:736-45. 10.1016/j.jhep.2008.11.018, 19231018.
10. Bonacini. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis 2004, 38(Suppl 2):S104-8. 10.1086/381453, 14986282.
11. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-48. 10.1001/jama.292.23.2839, 15598915.
12. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-9. 10.1056/NEJMoa032653, 15282352.
13. Marcellin F, Preau M, Dellamonica P, Ravaux I, Kurkdji P, Protopopescu C, et al. Adding HCV treatment to HIV treatment in HIV-HCV coinfected patients: the impact on the different dimensions of fatigue and self-reported side effects. J Pain Symptom Manage 2007, 34:413-21. 10.1016/j.jpainsymman.2006.12.014, 17616331.
14. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, Rios-Villegas MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007, 46:622-30. 10.1002/hep.21757, 17659577.
15. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009, 15:552-8. 10.1111/j.1365-2516.2008.01935.x, 2722242, 19347994.
16. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002. 10.1086/432762, 16107951.
17. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. Jama 2002, 288:199-206. 10.1001/jama.288.2.199, 12095384.
18. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615-24. 10.1016/j.jhep.2005.03.003, 15916745.
19. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003, 52:1784-7. 10.1136/gut.52.12.1784, 1773901, 14633963.
20. Galmiche JP. French consensus conference on hepatitis C: screening and treatment. Gut 1998, 42:892-8. 10.1136/gut.42.3.318, 1727138, 9691933.
21. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-75. 10.1016/S0140-6736(00)04258-6, 11297957.
22. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-13. 10.1016/j.ultrasmedbio.2003.07.001, 14698338.
23. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-50. 10.1053/j.gastro.2004.11.018, 15685546.
24. WHOQOL-HIV for quality of life assessment among people living with HIV and AIDS: results from the field test. AIDS Care 2004, 16:882-9. 10.1080/09540120412331290194, 15385243.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-9. 10.1007/BF00280883, 3899825.
26. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychology Measurement 1977, 3:385-491.
27. Michel L, Villes V, Dabis F, Spire B, Winnock M, Loko MA, et al. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008. J Viral Hepat 2010,
28. Salmon-Céron D, Gouëzel P, Delarocque-Astagneau E, Piroth L, Dellamonica P, Marcellin P, et al. Co-infection VIH-VHC à l'hôpital. Enquête nationale juin 2001. Médecine et Maladies Infectieuses 2003, 33:78-83.
29. From the Centers for Disease Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993, 269:729-30. 10.1001/jama.269.6.729, 8093740, From the Centers for Disease Control and Prevention.
30. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat 2006, 13:678-82. 10.1111/j.1365-2893.2006.00740.x, 16970599.
31. Cacoub P, Halfon P, Rosenthal E, Pialoux G, Benhamou Y, Perronne C, et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol 2008, 48:35-42. 10.1016/j.jhep.2007.07.028, 17945375.
32. Medrano J, Resino S, Vispo E, Madejon A, Labarga P, Tuma P, et al. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 2010,
33. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-50. 10.1056/NEJMoa040842, 15282351.
34. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009, 16:352-8. 10.1111/j.1365-2893.2009.01080.x, 19226330.
35. McLaren M, Garber G, Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can J Gastroenterol 2008, 22:133-7. 2659131, 18299730.
36. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008, 33:126-33. 10.1007/s10900-007-9083-3, 18165889.